Delving into the Latest Updates on ALLO-ASC-CD(Anterogen) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Stem cell replacements

Therapeutic Areas

Immune System DiseasesDigestive System Disorders

Active Indication

Crohn Disease

Inactive Indication-

Originator Organization

Anterogen Co., Ltd.

Active Organization

Anterogen Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Adipose-derived stem cells have properties of differentiation to various types of cells, immunomodulatory effects. adipose-derived stem cells (ASCs) show also low immunogenicity.
Anterogen has developed ANTG-ASC(Autologous ASC) which has shown good efficacy and safety in Phase I and II study on the patients with Crohn's fistula.
However, Crohn's patients are sometimes not fat enough to extract fat tissue for culturing ASCs. Therefore the investigators have planned to study allogenic ASCs for safety and efficacy in patients with Crohn's fistula.

Start Date01 Sep 2011

Sponsor / Collaborator

Anterogen Co., Ltd.

100 Clinical Results associated with ALLO-ASC-CD(Anterogen)

Login to view more data

100 Translational Medicine associated with ALLO-ASC-CD(Anterogen)

Login to view more data

100 Patents (Medical) associated with ALLO-ASC-CD(Anterogen)

Login to view more data

100 Deals associated with ALLO-ASC-CD(Anterogen)

Login to view more data